Advertisement
Research Article

Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B

  • Benjamin Matteson Vincent,

    Affiliations: Microbiology Graduate Program, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America

    X
  • Alex Kelvin Lancaster,

    Affiliation: Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America

    Current address: Department of Pathology, Beth Israel Deaconess Medical Center and Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Ruth Scherz-Shouval,

    Affiliation: Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America

    X
  • Luke Whitesell,

    Affiliation: Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America

    X
  • Susan Lindquist mail

    Lindquist_admin@wi.mit.edu

    Affiliations: Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States of America, Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America

    X
  • Published: October 29, 2013
  • DOI: 10.1371/journal.pbio.1001692
  • Featured in PLOS Collections

Reader Comments (1)

Post a new comment on this article

ERG mutations in C. tropicalis

Posted by Canadom on 07 Nov 2013 at 13:34 GMT

This is a quite remarkable paper. When looking at the ATTC AmB-resistant C. tropicalis isolate referred in this study, I observed that this ATCC strain was already investigated by Forastiero et al. (Antimicrobial Agents and Chemotherapy 2013. 57(10), 4769–4781). The authors found the same mutations that are reported in this Plos paper, just that the PLos paper report a 170-bp deletion in ERG11, while it is 132-bp in Forastiero et al, the last being more accurate. Strangely enough, another Amb-resistant C. tropicalis clinical isolate but of different geograpical origin was reported with exactly the same mutations than described by Forastiero et al. and this PLos paper (Eddouzi et al., Antimicrobial Agents and Chemotherapy, 2013, 57(7), 3182–3193). That two distinct clinical Candida isolates exhibit the same homozygous mutations on two different genes is quite unusual.

No competing interests declared.